Primary Cells Market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 10.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market can be attributed to factors such as the is government investments for cell-based research, rising growth in pharmaceutical biotechnology industries, increasing cancer research, increasing demand for monoclonal antibodies, increasing demand for personalized medicine, and growing advantages of primary human cells over cell lines.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960
Browse in-depth TOC on "Primary Cells Market"
179 - Tables
37 - Figures
222 - Pages
Primary Cells Market Scope:
Report Coverage | Details |
Market Revenue in 2023 | $1.7 billion |
Estimated Value by 2028 | $2.8 billion |
Growth Rate | Poised to grow at a CAGR of 10.5% |
Market Size Available for | 2021–2028 |
Forecast Period | 2023–2028 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Origin, Type, End-user, and Region |
Geographies Covered | North America, Europe, Asia Pacific, Rest of the World |
Report Highlights | Updated financial information / product portfolio of players |
Key Market Opportunities | Advancing biomedical research using primary cells in 3D cultures |
Key Market Drivers | Advantages of primary human cells over cell lines |
"In 2022, human primary cells segment accounted for the dominant share of the primary cells market, by origin."
On the basis of origin, the primary cells market is categorized into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the primary cells market. Factors responsible for the growth of the segment include the demand for accurate disease models, increasing application in studying cancer stem cells and drug-drug interactions in cancerous cells and circulating tumor cells, increasing the burden of chronic diseases, safety testing requirements, and ethical considerations.
"Hematopoietic cells segment accounted for the largest share in the primary cells market, by type in 2022."
On the basis of type, the primary cells market is divided into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. Hematopoietic cell transplants are frequently used to develop novel cancer therapies to treat blood cancers and other disorders of the immune system. Hematopoietic cells are also used to study the biochemical pathways of tumor cells and the efficacy of different drugs. This wide range of applications will contribute to the largest share of the hematopoietic cells in the primary cells market in 2022.
"In 2022, the pharmaceutical biotechnology companies, and CROs segment accounted for the largest share of the global primary cells market, by end user."
On the basis of end users, the primary cells market is segmented into pharmaceutical biotechnology companies, and CROs, academic research institutes, and other end users. In 2022, pharmaceutical biotechnology companies and CROs accounted for the largest share of the primary cells market, mainly due to the high adoption of primary cells among pharmaceutical biotechnology companies and CROs for cell-based experiments and cancer research.
"In 2022, North America is the largest regional market for primary cells."
The global primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the primary cells market. The increasing number of players launching new human primary cells for research, expansion in the pharmaceutical and biotechnology industries, rising incidences of cancer and various other chronic and infectious diseases, and the growing focus on RD in the region are the major factors driving the growth of the North American market. As life science research studies have significant use of primary cells, the growing focus on RD in this field is expected to drive market growth in North America during the forecast period.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960
Primary Cells Market Dynamics:
Drivers:
- Increasing cancer research
- Advantages of primary human cells over cell lines
- Increasing demand for monoclonal antibodies
- Rapid growth in biotechnology and biopharmaceutical industries
- Growing focus on personalized medicine
- Government investments for cell-based research
Restraints:
- Concerns regarding primary cell culture contamination
- Ethical concerns regarding research in cell biology
Opportunities:
- Advancing biomedical research using primary cells in 3D cultures
Challenges:
- Sourcing and availability of primary cells
Key Market Players:
Key players in the primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), ProMab Biotechnologies, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix (Switzerland), ReachBio LLC (US), AcceGen (US), AMSBIO (UK), and Kosheeka (India).
Recent Developments:
- In June 2023, iXCells Biotechnologies entered into an agreement with Tebubio to enhance the distribution of the company's products throughout Europe.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=32854960
